VBI Vaccines Announces Phase 2 Clinical Study Design of its Prophylactic CMV Vaccine Candidate
December 20, 2018 08:00 ET
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., Dec. 20, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
VBI Vaccines to Present Initial Data for VBI-1901 in Recurrent Glioblastoma (GBM) Patients at the 2018 Annual Meeting of the Society for Neuro-Oncology (SNO)
October 24, 2018 08:00 ET
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., Oct. 24, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...